N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-pyridyloxy)propyl]oxalamide		425	579
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1-oxido-4-pyridyloxy)propyl] oxalamide		441	580
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6-dimethyl-4-pyridyloxy)propyl] oxalamide		453	581
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6-dimethyl-1-oxido-4-pyridyloxy) propyl]oxalamide		469	582
N-[2-(4-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		435	583
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(2-methoxy-4-pyridyloxy)-1,1-dimethylpropyl] oxalamide		455	584
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4-(1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide		478	585
N-[3-(4-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	586
N-[2-(3-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		476	587
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[3-(1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide		478	588
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4-(1H-tetrazol-5-yl)phenoxy]propyl] oxalamide		492	589
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclobutyl]ethoxy]benzoate		570.2	590

Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoate		584.3	591
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoate		598.3	592
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoic acid		494.2	593
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoic acid		508.2	594
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclobutyl]ethoxy]benzoic acid		480.2	595
Benzyl 2-methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate		588	635
3-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		502	636
2-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		498	637
3-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		498	638
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopropyl]ethoxy]benzoic acid		466	639
2-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		502	640
4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid		519	641

(cis/trans)-4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-1-cyclohexanecarboxylic acid		474	642
(cis/trans)-4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]-1-cyclohexanecarboxylic acid		460	643
3-Fluoro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		486	644
3-Acetamido-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		525	645
3-(Methanesulfonamido)-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		561	646
4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-3,5-dimethylbenzoic acid		496	647
3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-2-pyridinecarboxylic acid		469	648
8-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid		519	649
5-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-2-indolecarboxylic acid		507	650

Examples 615-631 and 664-670

Example 615

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide.

(i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated

with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.

(ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 $[M+H]^+$.

Example 616 was prepared by an analogous method to that described for example 615 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

The additional compounds in table 1f[2] were prepared in an analogous manner to that described for example 615 by reaction of the appropriate thiol with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f[2]

Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide		426	615
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		442	616
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide		440	617

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-pyridylthio)ethyl]oxalamide		427	618
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2-pyridylthio)propyl]oxalamide		441	619
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2-thienylthio)propyl]oxalamide		446	620
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2-pyrimidylthio)propyl]oxalamide		442	621
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4-pyridylthio)propyl]oxalamide		441	622
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2-thiazolylthio)propyl]oxalamide		447	623
N-[3-(4-Hydroxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		456	624
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(5-methyl-1,3,4-thiadiazol-2-ylthio) propyl]oxalamide		462	625
N-[3-(2-Benzooxazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		481	626
N-[3-(2-Benzothiazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		497	627
Methyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoate		484	628
tert-Butyl 6-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylate		541	629
6-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)		485	630

4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]benzoic acid		484	631
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		532	664
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		546	665
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-5-benzoxazolecarboxylic acid		525	666
N-[3-(1H-Imidazol-2-ylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		430	667
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)		485	668
4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoic acid		470	669
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-6-benzoxazolecarboxylic acid		525	670

Examples 632-634

The compounds in table 1f[3] were prepared in an analogous manner to that described for example 398 in table 1f[1] by replacing the 4-nitrophenol with the appropriate aniline and reaction with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f[3]

Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino) ethyl] oxalamide		423	632
N-(3-Anilino-1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide hydrochloride (1:1)		423	633
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylamino]benzoic acid		467	634

Examples 407-414 ; 459-541 and 651-652

Typical methods used for the preparation of the compounds of table 1g are described below:

Example 408.

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide.

(i) A stirred solution of 3.23 g (16.8 mmol) of 1-(4-methoxyphenyl)piperazine, 2.00 g (16.8 mmol) of 2-methyl-2-nitropropan-1-ol and 5.34 g (50.4 mmol) of sodium carbonate in 40ml of n-butanol was refluxed for 16h. The reaction mixture was allowed to cool and diluted with 100ml of dichloromethane. The solution was filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using petroleum ether/ethyl acetate (10:1) for the elution to afford 1.86 g (6.34 mmol, 38%) of 1-(4-methoxyphenyl)-4-(2-methyl-2nitropropyl)piperazine as a white solid.

(ii) A solution of 1.86 g (6.34 mmol) of 1-(4-methoxyphenyl)-4-(2-methyl-2-nitropropyl)piperazine and 0.5 g of palladium on activated charcoal in 50 ml of ethanol was stirred at room temperature under an atmosphere of hydrogen for 48h. The reaction mixture was filtered and the filtrate concentrated in vacuo to afford 1.59 g (6.04 g mmol, 95%) of 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine as a clear oil. The 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to

afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide as a white solid. MS: m/e 508 $[M+H]^+$.

Examples 407, 409, 410, 411, 412 and similar structures were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with the appropriately substituted piperazine.

Examples 413 and 414 were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with t-butyl-1-piperazinecarboxylate to give 4-(2-amino-2-methylpropyl)piperazine-1-carboxylic acid t-butyl ester which was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid. The resulting product could then be deprotected to give N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide that could be used for the preparation of examples 413 , 414 and a variety of additional N-acyl and N-sulfonyl derivatives, such as those shown in table 1g, by using the appropriate acylating or sulfonylating reagent.

Example 489.

N-[2-[4-(Cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide.

A stirred solution of 48mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide (1.2mmol) and 13mg of cyclohexanecarboxaldehyde (1.2mmol) in 1ml of a 5% acetic acid / dichloromethane mixture was treated with a solution of 38mg of sodium triacetoxyborohydride (1.8mmol) in 1ml of a 5% acetic acid / dichloromethane mixture. After stirring overnight at room temperature the reaction mixture was diluted with 10ml of dichloromethane and washed with 8ml of a sodium bicarbonate solution followed by 8ml of water. The organic layer was then evaporated and purified using flash chromatography on a silica gel column eluting with 5% methanol / dichloromethane to give after evaporation of the fractions 14.3mg (0.3 mmol, 25%) of N-[2-[4-(cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide in the form of a white solid. MS: m/e 498.2 $[M+H]^+$.

Additional N-alkylated compounds shown in table 1g were prepared by analogous methods.

table 1g

Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	407
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	408
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	409
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-phenyl-1-piperazinyl)propyl]oxalamide		492	410
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	411
N-[2-(4-Benzyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		492	412
N-[2-[4-(Benzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		452	413
N-[2-(4-Benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		506	414
N-[2-[4-[4-(Trifluoromethyl)phenyl]-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		546	459
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	460

N-[2-[4-(2-Fluorophenyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		496	461
N-[2-[4-(4-Fluorophenyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		496	462
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	463
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-thiophenesulfonyl)-1-piperazinyl]ethyl]oxalamide		548	464
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2,4,6-trimethylbenzenesulfonyl)-1-piperazinyl]ethyl]oxalamide		584.1	465
N-[2-[4-(4-Fluorobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		560.1	466
N-[2-[4-(Trifluoromethanesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl)]oxalamide		534	467
N-[2-[4-(Isopropylsulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl)]oxalamide		508.1	468
(E)-N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(styrylsulfonyl)-1-piperazinyl]ethyl]oxalamide		568.1	469
N-[2-[4-(Ethanesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		494.1	470
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(propanesulfonyl)-1-piperazinyl]ethyl]oxalamide		508.1	471
N-[2-[4-(3-Chloropropanesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		542.1	472

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(o-toluenesulfonyl)-1-piperazinyl]ethyl]oxalamide		556.1	473
N-[2-[4-(2-Fluorobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		560.1	474
N-[2-[4-(2-Cyanobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		567.1	475
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3,5-dimethyl-4-isoxazolylsulfonyl)-1-piperazinyl]-1,1-dimethyl-ethyl]oxalamide		561.1	476
N-[2-[4-(5-Fluoro-2-methylbenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		574.1	477
N-[2-[4-(2,5-Difluorobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		578.1	478
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(1-methyl-1H-imidazole-4-sulfonyl)-1-piperazinyl]ethyl]oxalamide		546.1	479
N-[2-[4-(2,6-Difluorobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		578.1	480
N-[2-[4-(3,4-Difluorobenzenesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		578.1	481
N-[2-[4-(Cyclohexylmethanesulfonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		562.2	482

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-phenylethanesulfonyl)-1-piperazinyl]ethyl]oxalamide		570.1	483
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		538	484
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(4-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	485
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2,4-dimethylphenyl)-1-piperazinyl]ethyl]oxalamide		506	486
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3,4-dimethoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		538	487
N-[2-(4-Cyclohexyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		484.4	488
N-[2-[4-(Cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		498.2	489
N-[2-[4-(2-Methoxybenzyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		522.1	490
N-[2-[4-(2-Hydroxybenzyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		508.1	491
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylbenzyl)-1-piperazinyl]ethyl]oxalamide		506.1	492
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-thenyl)-1-piperazinyl]ethyl]oxalamide		498.1	493
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2(RS)-phenylpropyl)-1-piperazinyl]ethyl]oxalamide		520.2	494

N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-pivaloyl-1-piperazinyl)ethyl]oxalamide		486.1	495
N-[2-[4-(2-Furoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		496.1	496
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-thenoyl)-1-piperazinyl]ethyl]oxalamide		512.1	497
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(3-thenoyl)-1-piperazinyl]ethyl]oxalamide		512	498
N-[2-[4-(2-Cyclopentylacetyl)-1-piperazinyl]-1,1-dimethyl-ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl)]oxalamide		512.1	499
N-[2-[4-(Cyclohexylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		512.1	500
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylbenzoyl)-1-piperazinyl]ethyl]oxalamide		520.1	501
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(4-methylbenzoyl)-1-piperazinyl]ethyl]oxalamide		520.1	502
N-[2-[4-(Cycloheptylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		526.2	503
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-]1,1-dimethyl-2-[4-[(1H-pyrazol-4-yl)carbonyl]-1-piperazinyl]ethyl]oxalamide		496.1	504
N-[2-[4-(Cyclopentylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		498.1	505
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-Dimethyl-2-[4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1-piperazinyl]ethyl]oxalamide		509.1	506

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(1,2,3-thiadiazol-4-yl)carbonyl]-1-piperazinyl]-ethyl]oxalamide		514.1	507
N-[2-[4-(3-Fluorobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		524.1	508
N-[2-[4-(4-Fluorobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		524.1	509
N-[2-[4-(Cyclopropylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		470.1	510
N-[2-[4-(2-Cyclohexylacetyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		526.2	511
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3,3-dimethylbutyryl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		500.2	512
N-[2-[4-(3-Hydroxy-2,2-dimethylpropionyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		502.1	513
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(3-methyl-2-furoyl)-1-piperazinyl]ethyl]oxalamide		510.1	514
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methyl-3-furoyl)-1-piperazinyl]ethyl]oxalamide		510.1	515
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(5-methyl-1H-pyrazol-3-yl)carbonyl]-1-piperazinyl]ethyl]oxalamide		510.1	516
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(5-methyl-4-isoxazolyl)carbonyl]-1-piperazinyl]ethyl]oxalamide		511.1	517

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(5-methyl-3-isoxazolyl)carbonyl]-1-piperazinyl]ethyl]oxalamide		511.1	518
N-[2-[4-(4-Aminobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		521.1	519
N-[2-[4-(2-Hydroxybenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		522.1	520
N-[2-[4-(4-Hydroxybenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		522.1	521
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(2,5-dimethyl-2H-pyrazol-3-yl)carbonyl]-1-piperazinyl]ethyl]oxalamide		524.1	522
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(3-methyl-2-thenoyl)-1-piperazinyl]ethyl]oxalamide		526.1	523
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(4-methyl-2-thenoyl)-1-piperazinyl]ethyl]oxalamide		526.1	524
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(2,2,3,3-tetramethyl-1-cyclopropyl)carbonyl]-1-piperazinyl]ethyl]oxalamide		526.2	525
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-1-piperazinyl]ethyl]oxalamide		528.1	526
N-[2-[4-(3-Cyanobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		531.1	527
N-[2-[4-[(Bicyclo[4.2.0]octa-1(6),2,4-trien-7-yl)carbonyl]-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		532.1	528

N-[2-[4-(3-Hydroxybenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		522.1	529
N-[2-[4-(2-Ethylbutyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		486.1	530
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]oxalamide		506.2	531
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[3-(methylthio)propyl]-1-piperazinyl]ethyl]oxalamide		490.1	532
N-[2-[4-(2,6-Difluorobenzyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		528.1	533
N-[2-[4-(3-Furfuryl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		482.1	534
N-[2-[4-[(2-Benzofuranyl)methyl]-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl)]oxalamide		532.1	535
N-[2-[4-(2-Cyanobenzyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		517.1	536
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3,3-dimethylbutyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		486.2	537
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-[(2-quinolinyl)methyl]-1-piperazinyl]ethyl]oxalamide		543.2	538
tert-Butyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazineacetate		516	539
4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazineacetic acid trifluoroacetate (1:1)		460	540

N-[2-[4-(Cyclopropylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		456	541
tert-Butyl 4-[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl] benzoate		578	651
4-[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoic acid trifluoroacetate (1:1)		522	652

Examples 415-420:

In a manner analogous to that described in Example 4 starting with N-[3-(aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide and the appropriate carboxylic acid chloride compounds shown in table 1h were prepared.

table 1h

Name	Structure	ME(ES) $(M+H)^+$	Ex No
Phenyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl] carbamate		487	415
N-[3-[(3-Fluorobenzamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		489	416
N-[3-[(3-Chlorobenzamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		505	417
N-[3-[(3-Methoxybenzamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		501.2	418
N-[3-[(3,4-Dimethoxybenzamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		531.2	419

N-[3-[(3-Cyanobenzamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		496.1	420

Examples 421-427 and 598-614 :

Typical methods used for the preparation of the compounds of table 1b are described below:

Examples 421 and 423 were prepared by reaction of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide with the appropriate acylating reagent.

Example 424 was prepared in a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid, prepared as described in Example 1, parts (i) and (ii), and the appropriate amine.

Example 422

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide.

(i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.

(ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 $[M+H]^+$.

Example 427 was prepared by an analogous method to that described for example 422 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

Example 607 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1.

Example 426 was prepared in a manner analogous to that described for example 408 in table 1g using tetrahydro quinoline in place of 1-(4-methoxyphenyl)piperazine.

Example 610

N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of N-ethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an off-white solid. MS m/e 479 $[M+H]^+$.

The starting material was prepared as follows:

i) A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue

was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid. ^{1}H NMR (400 MHz $CDCl_3$) δ: 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).

ii) 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. ^{1}H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).

iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. ^{1}H NMR (400 MHz $CDCl_3$) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).

iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate

solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 $[M+H]^+$.

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an off-white solid. MS: m/e 401 $[M+H]^+$.

Example 616 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1

Example 619

N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of N-ethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an off-white solid. MS m/e 479 $[M+H]^+$.

The starting material was prepared as follows:

i) A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid. ^{1}H NMR (400 MHz $CDCl_3$) δ: 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).

ii) 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. ^{1}H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).

iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. ^{1}H NMR (400 MHz $CDCl_3$) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).

iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-

ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 $[M+H]^+$.

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an off-white solid. MS: m/e 401 $[M+H]^+$.

The remaining examples in table 1b were prepared by methods analogous to those described above, as appropriate to the structure, or by methods previously described for related structures.

table 1b

Name	Structure	MS(ES) $(M+H)^+$	Ex No
Benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate		535	421
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide		426	422
N-[2-(1-Acetyl-4-piperidinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		443	423

N-(2-Cyclohexyl-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		400	424
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino)ethyl]oxalamide		423	425
N-[2-(1,2,3,4-Tetrahydro-1-quinolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		449	426
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		442	427
N-[3-(4-Hydroxyphenyl)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		424	598
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[(1-oxido-4-pyridyl)carboxamido] ethyl]oxalamide		454	599
N-[2-(4-Acetylbenzamido)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		479.1	600
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-[(4-methylbenzamido)methyl]phenyl]oxalamide		485.1	601
N-[3-[(2-Methoxybenzamido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		501.1	602
N-[3-[(4-Chlorobenzmido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		505.1	603
N-[3-[[(1,3-Benzodioxol-5-yl)carboxamido]methyl]phenyl] -N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		515.2	604

N-[2-(2,3-Dihydro-1-indolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		435	605
N-[2-(3,4-Dihydro-6-methyl-2H-quinol-1-yl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		463	606
N-[1-(3-Benzofuranyl)-1-methylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		420	607
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4-phenoxypiperidino)propyl]oxalamide		507	608
N-[2-(1-Butyryl-4-piperidinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		471	609
N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		479	610
N-[2-[1-(Benzenesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		541	611
N-[2-(1-Isobutyryl-4-piperidinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		471	612
tert-Butyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino] oxalyl] amino]-3-methylbutyl]-1-piperidinecarboxylate		515	613
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4-piperidinyl)propyl]oxalamide		415	614

Examples 428-432:

Examples 428, 431 and 432 of table 1i were prepared in a manner analogues to that described for example 408 in table 1g but using N-[3-methoxy-4-(4-oxazoyl)phenyl oxalamic acid or N-[3-methoxy-4-(2-methyl-4-oxazoyl)phenyl oxalamic acid in place of N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid for the coupling step.

Examples 429 and 430 of table 1i were prepared by analogues procedures to those described for the preparation of the compounds of table 1f.

table 1i

Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	428
N-[2-(4-Benzyloxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		500	429
N-[2-(4-Hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		410	430
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	431
N-[3-Methoxy-4-(2-methyl-4-oxazolyl)-phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		522.4	432

The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.